This report from Life Science Intelligence provides the latest market data for the Global Embolization Agents Market. Information covered by this report includes:
The global market for embolization agents was valued at an estimated $588.3 million in 2020 and is projected to increase at a CAGR (2020-2024) of 7.7%. Product segments covered by this report include embolization particles and liquid embolics. Embolization agents are used to treat tumors, uterine fibroids, and vascular malformations.
This report covers the impact of COVID-19 on the embolization agents market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Boston Scientific, Merit Medical, Medtronic, Sirtex, and others. The report provides insights into trends, drivers, and limiters of the embolization agents market, as well as highlights potential opportunities.
The COVID-19 pandemic had a slightly negative impact on the global embolization agents market. Embolization agents are primarily utilized for the treatment of critically ill patients with life threatening conditions (i.e. stroke, liver cancer), and therefore were less negatively impacted by the pandemic
Boston Scientific and Sirtex are the leading competitors in the global embolization agents market. Together these two companies account for more than 80% of the global market share. Sirtex is the market leader for targeted radioembolization of inoperable liver tumors and has supplied more than 100,000-unit doses to treat liver cancer patients worldwide and continues to expand its penetration in large markets like China, Japan, and South America.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
